When Good Goes Awry: The Aggregation of Protein Therapeutics
Aggregation, Antibodies, Delivery, Formulation, Glucagon, Insulin, Storage.
Protein therapeutics are playing an increasingly important role in treatment of a variety of human diseases. However, like the rest of proteins, they are susceptible to aggregation. Aggregation of proteinaceous pharmaceuticals can cause a loss of efficacy and, potentially, cytotoxicity and an immunogenic response. This review describes various ways protein therapeutics aggregate and a variety of approaches taken to prevent or minimize this process.
Was this content written or created while at USF?
Citation / Publisher Attribution
Protein & Peptide Letters, v. 24, issue 4, p. 340-347
Scholar Commons Citation
Redington, Jeniffer M.; Breydo, Leonid; and Uversky, Vladimir N., "When Good Goes Awry: The Aggregation of Protein Therapeutics" (2017). Molecular Medicine Faculty Publications. 861.